Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Ann Surg Oncol. 2020 Jan 13;27(5):1496–1507. doi: 10.1245/s10434-019-08176-z

Table 2:

Frequency of Esophaaectomv Marqin Positivity bv Sample Characteristics

Negative Margin Positive Margin p-value*

N (%)

Total Cases 26,924 (90.63%) 2,782 (9.37%)
Age
   <55 5,578(91.44%) 522 (8.56%) <0.001
   55–64 9,423(91.61%) 863 (8.39%)
   65–74 8,671 (90.95%) 863 (9.05%)
   ≥75 3,252 (85.90%) 534(14.10%)
Sex
   Male 22,386 (90.66%) 2,305 (9.34%) 0.696
   Female 4,538(90.49%) 477(9.51%)
Race
   White 24,276 (90.82%) 2,455 (9.18%) 0.004
   Black 1,092(88.28%) 145(11.72%)
   Hispanic 716 (88.50%) 93 (11.50%)
   Other 840 (90.42%) 89 (9.58%)
Insurance Status
   Medicaid/Medicare 12,719(89.33%) 1,519(10.67%) <0.001
   Private 12,772 (92.14%) 1,090 (7.86%)
   Other Government 442 (90.39%) 47 (9.61%)
   Uninsured 547 (87.94%) 75 (12.06%)
Charlson-Deyo Index
   0 19,724 (90.75%) 2,010 (9.25%) 0.001
   1 5,706 (90.95%) 568 (9.05%)
   2 1,164(88.52%) 151 (11.48%)
   ≥3 330 (86.16%) 53 (13.84%)
Median Zip Code Income
   <38,000 3,949(89.69%) 454(10.31%) 0.039
   38,000–47,999 6,557(90.84%) 661 (9.16%)
   48,000–62,999 7,763 (90.59%) 786(9.41%)
   >63,000 8,472(91.19%) 818(8.81%)
Quartile of Distance to Hospital (miles)
   1 (<1–7.3) 6,671 (89.92%) 748(10.08%) <0.001
   2(7.4–18.5) 6,564 (90.46%) 692 (9.54%)
   3(18.6–49.8) 6,596(90.57%) 687 (9.43%)
   4 (≥49.9) 6,723(91.87%) 595(8.13%)
Facility Type
   Academic/Research 14,601 (91.40%) 1,373 (8.60%) <0.001
   Integrated Network Cancer Program 2,710(90.76%) 276 (9.24%)
   Comprehensive Community Cancer Program 7,965(89.85%) 900(10.15%)
   Community Cancer Program 1,275 (87.51%) 182 (12.49%)
Hospital Location
   Metro 20,910(90.75%) 2,132 (9.25%) 0.444
   Urban 4,475(90.31%) 480 (9.69%)
   Rural 582 (91.65%) 53 (8.35%)
Histologic Morphology
   Adenocarcinoma 21,741 (90.97%) 2,158 (9.03%) <0.001
   Squamous Cell Carcinoma 4,293(88.81%) 541 (11.19%)
   Carcinoma NOS 890 (91.47%) 83 (8.53%)
Tumor Location

   Upper Third 451 (81.26%) 104(18.74%) <0.001

   Middle Third 2,877 (89.63%) 333(10.37%)

   Lower Third 20,554 (91.37%) 1,941 (8.63%)

   Overlapping Sites/NOS 3,042 (88.28%) 404(11.72%)

Clinical T Stage

   Tis 849 (90.90%) 85 (9.10%) <0.001

   T1 5,021 (90.91%) 502 (9.09%)

   T2 3,966 (92.86%) 305 (7.14%)

   T3 10,224 (92.07%) 880 (7.93%)

   T4 507 (85.07%) 89 (14.93%)

Clinical N Stage

   NO 12,147 (90.98%) 1,205 (9.02%) <0.001

   N1 8,084(92.15%) 689 (7.85%)

   N2 1,227(93.38%) 87 (6.62%)

   N3 212 (88.70%) 27 (11.30%)

Tumor Grade

   Well Differentiated 2,078(93.06%) 155 (6.94%) <0.001

   Moderately Differentiated 9,647(91.69%) 874(8.31%)

   Poorly Differentiated 9,929 (88.22%) 1,326(11.78%)

   Undifferentiated 377 (88.92%) 47 (11.08%)

Tumor Size3

   ≤2.0 6,244 (92.34%) 518(7.66%) <0.001

   2.1–4.0 6,289 (90.49%) 661 (9.51%)

   4.1–6.0 4,016(89.01%) 496(10.99%)

   >6.0 2,545 (86.27%) 405(13.73%)

Neoadjuvant Therapy

   No 11,768 (86.93%) 1,769(13.07%) <0.001

   Yes 15,156 (93.73%) 1,013 (6.27%)

Surgical Approacha

   Open 7,021 (92.88%) 538 (7.12%) <0.001

   Laparoscopic 4,064 (87.93%) 558(12.07%)

   Robotic 828 (96.28%) 32 (3.72%)

Mean Annual Hospital Esophagectomy Volume Quartile (n/year)

   1 (≤2) 6,684(88.61%) 859(11.39%) <0.001

   2 (2.1–5.4) 6,679(90.18%) 727 (9.82%)

   3(5.5–13.3) 6,746(91.55%) 623 (8.45%)

   4 (>13.3) 6,807 (92.24%) 573.76%)

chi2 test

cm = centimeter

a

surgical approach available beginning in 2010